Ocular Therapeutix, INC

Ocular Therapeutix announced the resignation of its Chief Strategy Officer, Sanjay Nayak, effective October 16, 2026, to pursue a CEO position at another company.

Ocular Therapeutix announced a clear FDA-aligned path for its AXPAXLI NDA submission in Q4 2026, supported by positive Phase 3 data and a strong cash position extending into 2028.

Ocular Therapeutix confirmed the appointment of Jason Robins as CFO and secured shareholder approval for a 10 million share increase to its 2021 Stock Incentive Plan.

Ocular Therapeutix reported Q1 2026 financial results, highlighting positive Phase 3 SOL-1 trial data for AXPAXLI in wet AMD and providing updates on ongoing clinical programs.

Ocular Therapeutix, Inc. announced it will present detailed Phase 3 clinical trial results for AXPAXLI in wet age-related macular degeneration at the 49th Macula Society Annual Meeting.

Ocular Therapeutix announced its fourth quarter and full year 2025 financial results, highlighted by upcoming Phase 3 trial data for AXPAXLI in wet AMD and a strong cash position.

Ocular Therapeutix reports progress in its AXPAXLI clinical trials for wet AMD and diabetic retinopathy, alongside Q2 2026 financial results showing increased R&D spending and continued net losses.

Ocular Therapeutix reports positive Q1 2026 results, driven by strong clinical trial data for AXPAXLI and modest growth in DEXTENZA revenue, while managing increased R&D expenses.

Ocular Therapeutix reports Q3 2025 financial results, highlighting a significant capital raise and continued progress in its late-stage retinal disease clinical programs for AXPAXLI.

Ocular Therapeutix, Inc. reported increased net losses and decreased product revenue in Q2 2025, driven by significant R&D investments in its late-stage retinal disease programs, while extending its cash runway into 2028.

Ocular Therapeutix announces its Q1 2025 financial results, focusing on the advancement of its AXPAXLI clinical trials and the commercial performance of DEXTENZA.

Ocular Therapeutix's Q3 2024 report shows a slight increase in product revenue and significant advancements in clinical trials for their key product candidates.

Ocular Therapeutix's 2025 annual report reveals widening net losses and declining DEXTENZA revenue, despite significant advancements in its AXPAXLI clinical programs and a substantial capital raise.

Ocular Therapeutix provides an update on its key programs, including AXPAXLI's Phase 3 trials and DEXTENZA's pediatric study submission, in its annual 10-K filing.

Ocular Therapeutix appoints new executives, provides updates on clinical trials, and reports financial results.

Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc, sold 11,984 shares of common stock on October 8, 2026 for $7.29 per share.

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc, sold 9,990 shares of common stock on October 2, 2026 for $7.05 per share.

Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc, sold 10,869 shares of common stock on October 2, 2026 for $7.05 per share.

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc, sold 3,035 shares of common stock on August 24, 2026 for $10.77 per share.

Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, Inc, sold 1,897 shares of common stock on August 24, 2026 for $10.78 per share.

Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc, sold 3,296 shares of common stock on August 24, 2026 for $10.78 per share.

Ocular Therapeutix, Inc. filed its 2026 proxy statement detailing executive compensation, director elections, and a proposal to increase the 2021 Stock Incentive Plan by 10 million shares.

Ocular Therapeutix has scheduled its annual stockholders meeting for June 11, 2025, and is seeking votes on director elections, executive compensation, stock incentive plan amendments, and other corporate matters.

Ocular Therapeutix is seeking stockholder approval for several key proposals at its 2025 Annual Meeting, including amendments to its stock incentive plan, employee stock purchase plan, and certificate of incorporation to provide officer exculpation.

Ocular Therapeutix is holding its annual meeting on June 12, 2024, seeking stockholder approval for director elections, executive compensation, an increase in stock incentive plan shares, an increase in authorized common stock, and ratification of its accounting firm.

Ocular Therapeutix is holding its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on several proposals, including the election of directors, executive compensation, and amendments to the stock incentive plan and corporate charter.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 9.53% of Ocular Therapeutix, Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Ocular Therapeutix Inc. due to an internal corporate realignment.

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a beneficial ownership of 5.13% in Ocular Therapeutix, Inc.

Deep Track Capital and its affiliates have reported a beneficial ownership of 4.31% in Ocular Therapeutix, Inc., indicating a reduction below the 5% threshold.

Summer Road LLC, a Delaware family office, has reported a 5.7% beneficial ownership stake in Ocular Therapeutix, Inc., totaling 12,134,357 common shares.

Venrock Healthcare Capital Partners and affiliates report a 7.3% beneficial ownership stake in Ocular Therapeutix Inc., totaling 12.9 million shares.